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Background: There is conflicting data regarding the mortality benefit of statins in patients with heart failure.
The objectives of our study were to determine whether statin therapy is associated with decreased all-cause
mortality and to assess the effect of incremental duration of therapy.
Methods:We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of
heart failure from January 2002 through December 2006. Mean follow‐up was 2.66 years. Statin use and
duration of therapy were identified. Veterans were classified into four groups based on duration of statin use
during the study period (none, 1–25%, 26–75% and N75% use of statins). Logistic regression was performed to
identify the association between incident statin use and all-cause mortality following a diagnosis of heart
failure. The Kaplan–Meier method was employed to assess for differences in survival time between the four
statin use classifications.
Results: Statin use was significantly associated with decreased all-cause mortality following a diagnosis of
heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ32
(N=10,510)=1077.82, pb0.001]. The benefit was seen within a relatively short duration (within 1 year)
after starting statins, and in patients with b25% use of statins, there was no mortality benefit.
Conclusion: Veterans who were not exposed to statin therapy at any time during the study period were 1.56
times more likely to suffer all–cause mortality.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Background
Large randomized trials on statins have excluded patients with
heart failure. It is well-known that statins effectively lower low-
density lipoprotein levels. But there is increasing evidence of
“pleiotropic” effect of statins that could affect the outcome in heart
failure patients. At molecular level, statins are associated with both
beneficial and harmful effects. Heart failure is associated with
evidence of systemic inflammation, which is evident in the form of
increase in proinflammatory markers such as interleukin-6, tumor
necrosis factors and C-reactive protein. Statins decrease these
proinflammatory markers [1,2]. Statins decrease the free radical
production, which have been suggested to have causal role in
development of heart failure [3]. Statins increase nitric oxide
production by stimulation of endothelial nitric oxide synthase,
which has been linked to myocardial perfusion, vasodilatation, and
LV remodeling [4]. Statins decrease myocyte hypertrophy, attenuate
LV remodeling and myocardial fibrosis [5,6]. Treatment with statins is
associated with decreased angiotensin I mediated vasoconstriction,
enhanced response to angiotensin receptor blockage drugs [7]. Statins
are associated with decreased incidence of atrial fibrillation, ventric-
ular arrhythmias, or sudden cardiac death [8,9].
There are potential harmful effects of statins. These include
decrease in circulating cholesterol and triglyceride rich lipoproteins,
which have the ability to detoxify endotoxins [10]. Statin causes
reductions in levels of coenzyme Q10, which has been linked to
protection from free radical injury [11]. It also decreases selenoprotein
levels that could lead to skeletal and cardiac myopathy [12].
There is conflicting evidence regarding the benefit of statins in
patients with congestive heart failure [13–20]. The main limitation of
large databases is that statin therapy was recorded at a single time of
the study, mostly on discharge diagnosis. As shown in the myocardial
infarction trials with statin, the mortality increases in patients when
statins are discontinued [21].
CORONA study has raised doubts on the effects of statins on heart
failure patients, but the study population consisted of elderly patients
with only ischemic heart failure, where the disease might have been
too advanced to modify [22]. Compliance with statin therapy has
been a major confounder in the observational studies and GISSI-HF
randomized controlled trial [23]. Both randomized control trials have
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evaluated the effect of one type of statin (rosuvastatin) on heart
failure and there is no conclusive evidence of a class effect of statins
[24]. With all the available evidence, further studies are needed to
determine the effect of statins in patients with heart failure.
The primary objective of our study was to evaluate the effect of
statins on mortality in a large group of patients with heart failure in a
usual care setting. The secondary objective was to evaluate the
incremental duration of statin therapy on mortality in heart failure.
2. Methods
2.1. Study design and sample
A retrospective cohort design was used to examine veterans diagnosed with heart
failure during the five-year period from January 1, 2002 through December 31, 2006
using administrative data abstracted from the Veterans Affairs Midwest Health Care
Network (Veterans Integrated Service Network, VISN 23). (Deleted local details of the
VA network as per reviewer's request along with previous reference number 25 from
the initial manuscript).
2.2. Inclusion criteria
Veterans were included in the study if they met the following criteria: 20 years of
age or older and one or more hospitalizations with either a primary or secondary
diagnosis of heart failure (ICD-9-CM codes of 398.91, 402.01, 402.11, 402.91, 428.0,
428.1, or 428.9) or a primary diagnosis of heart failure during an outpatient visit. The
heart failure index date (HF-ID) was defined as the first diagnosis of heart failure (HF)
and one previous outpatient/inpatient visit with no primary or secondary diagnosis of
HF.
2.3. Exclusion criteria
Veterans who were censored within 180 days of heart failure diagnosis were
excluded from the study (i.e., the veteran must have remained alive 180 days following
heart failure diagnosis, with diagnosis prior to July 5, 2006).
A total of 10,510 veterans met the inclusion criteria. However, the date of statin
therapy initiation was unknown in some patients with heart failure. We identified a
cohort of 5282 veterans with heart failure who initiated statin therapy after their
respective HF-ID. This cohort did not receive any statin therapy for at least 120 days
prior to HF-ID. A subsequent subgroup analysis was performed to eliminate the bias of
previous statin therapy on the outcome in patients with heart failure. The study flow is
represented in Fig. 1.
The demographic and health care information over the five-year period for this
cohort of veterans was exported into a database created specifically for the study. The
data were obtained from the VISN 23 Data Warehouse using the VA Computerized
Patient Record System (CPRS). CPRS contains all components of a patient's medical
records including but not limited to demographic information (including mortality
date), clinical procedures, laboratory and diagnostic test results, decision support,
pharmaceutical utilization (bar code medication administration), progress notes,
appointments, International Classification of Diseases-Ninth Revision-Clinical Modifi-
cation (ICD-9-CM) codes for diagnoses and procedures, and Diagnosis Related Groups
(DRGs).
2.4. Stratification of statin use
Statin use was defined as filling one or more statin prescription (i.e., fluvastatin,
lovastatin, pravastatin, simvastatin, atorvastatin, or rosuvastatin) during the 3 months
prior to HF-ID (e.g., October 1, 2001 for an HF-ID of January 1, 2002) or anytime
thereafter up to the study end date of December 31, 2006. Pharmacy refill data were
abstracted from the VA Decision Support System (DSS) National Data Extract (NDE)
SAS Datasets and included both inpatient and outpatient prescriptions dispensed by a
VA Medical Center Pharmacy or a Veterans Affairs Consolidated Mail Outpatient
Pharmacy (CMOP) [25]. (Changed reference number due to deletion of previous
reference number 25).
Longitudinal statin use was estimated as the percentage of time quantified from
refill patterns based on refill dates and quantity/supply. The maximum number of days
a veteran could remain on statin therapy was calculated as the number of days from
therapy initiation until end of follow up (i.e., December 31, 2006) or death. The total
number of days the veteran was not on a statin was then subtracted, and this difference
was divided by the maximum number of days and multiplied by 100, yielding the
percentage of statin use following initiation of statin therapy during the study period.
Individuals were then stratified exclusively into one of four possible groups: Nonusers
(no statin prescription filled between October 1, 2001 and December 31, 2006), ≤25%,
N25% to 75% statin use and N75% statin use.
2.5. Covariates
Date of birth, race, and gender were abstracted from the CPRS. Forty-eight percent
of the race data were missing and preliminary assessment indicated the data were
missing not at random (MNAR) precluding the option of replacing the missing data
through traditional approaches (i.e., imputation or maximum likelihood estimate
modeling) [26,27]. Thus, race was dropped from analyses, resulting in gender and age
at HF-ID as the demographic covariates. Comorbid conditions were identified from
diagnoses using ICD-9 codes as either a principal or secondary diagnosis of coronary
heart disease, atrial fibrillation, cerebrovascular disease, hemorrhagic stroke, connec-
tive tissue disease, diabetes, hypertension, coronary artery disease, hyperlipidemia,
depression, chronic kidney disease, liver disease, lung disease, malignancies, peripheral
arterial disease, peptic ulcer disease, HIV, dementia, and sudden cardiac death.
Concurrent cardioprotective medications were controlled for during the 3 months prior
to January 1, 2002 and anytime thereafter up to the study end date of December 31,
2006. These medications included beta blockers, angiotensin converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARB), aspirin (ASA), and spironolactone. The
method of using prescription refill and quantity/supply data to calculate percentage of
concurrent medication use for individual medications was analogous to statin use
described above, except these percentages were not stratified but rather analyzed as
continuous variables.
3. Statistical analysis
Statistical analysis was performed using SPSS 15.0 (SPSS Inc,
Chicago, IL). Continuous variables are presented as mean±SD and
categorical variables are presented as numbers (%). We compared
descriptive characteristics among all veterans included in the study
period using the Kruskal–Wallis test for continuous data and the chi-
square test for nominal data. A two-sided p value of less than 0.05
indicated significance for omnibus tests. When necessary, post hoc
tests (i.e., the Mann–Whitney test for continuous data and Fisher's
exact test for categorical data) were conducted employing a
Bonferroni adjustment to control for multiple comparisons; thus,
significant post hoc tests were indicated by a two-sided p value less
than 0.008.
The survival function for each statin use stratification was
summarized using the Kaplan–Meier method. For the omnibus log-
rank test, a two-sided p value less than 0.05 indicated statistical
significance. Pairwise comparisons, using a Bonferroni adjustment,
were employed to identify group differences, with a two-sided p value
of 0.008 indicating statistical significance. At the end of the study
period, sequential logistic regression was used to model all-cause
mortality by the four statin use stratifications controlling for the
covariates described previously.
4. Results
A total of 10,510 veterans with heart failure were identified during the five-year
study period from January 1, 2002 through December 31, 2006. This cohort was
predominantly male (98.4%) with a mean age of 72.0 years and an all-cause mortality
rate of 25.8%. The average individual had a mean of 973.4 days (2.66 years) in the study
post HF-ID, was on two cardioprotective medications, and had four comorbid
conditions. Statin therapy was initiated in 71.0% of these veterans.
Statin users were further stratified by the percentage of time they remained on
statin therapy during the study period, as described previously. Descriptive statistics for
this cohort are displayed in Table 1. Post hoc tests indicated statin nonusers were older
and had higher mortality rates in comparison to statin users (pb0.001 for each
stratification respectively). Further, statin nonusers were less likely to be on concurrent
medications compared to veterans who remained on statin therapy N25% of the time
during the study period (pb0.001 for all comparisons). Statin nonusers were less likely
to have a comorbid diagnosis of coronary artery disease, hyperlipidemia, and
Statin use (start date not available)
N=10510
HF-ID date (inpatient: primary/secondary HF diagnosis or
       
N=5282
Statin started (no statin for at least 120 days
prior to HF-ID)
outpatient: primary HF diagnosis)
Fig. 1. Study flow.
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hypertension in comparison to all statin use stratifications (all pb0.001). However,
statin nonusers were more likely to have a diagnosis of atrial fibrillation, lung disease,
and malignancy compared to patients remaining on statin therapy (all pb0.001).
Duration of statin use as a predictor of all-cause mortality: The Kaplan–Meier
method was employed to assess for differences in survival time following a diagnosis of
heart failure between the four statin use stratifications. The omnibus Mantel–Cox log-
rank test indicated significant differences in survival time (χ32=307.2, pb0.001; Fig. 2).
Analysis of pairwise comparisons indicated survival time for veterans who did not
initiate statin therapy during the study period was significantly shorter in comparison to
statin users, regardless of the percentage of time on statin (all pb0.001).
Sequential logistic regression was performed to identify the association between
duration of statin use and all-cause mortality among veterans with heart failure
controlling for age, gender, concurrent medications, and comorbid conditions
described above. Evaluation of adequacy of expected frequencies for categorical
covariates revealed no need to restrict model goodness-of-fit tests and no serious
violation of linearity of the logit was observed.
The addition of the statin use stratifications to the logistic model significantly
improved prediction of all-cause mortality (χ32=87.7, pb0.001). Overall, the results
indicated the variables, as a set, are significantly associated with all-cause mortality
(χ32=1078.1, pb0.001); however, the variance in mortality accounted for by the model
is small (Nagelkerke R2=0.143, with a 95% confidence interval for the effect size
ranging from 0.121 to 0.157) [28]. Table 2 displays the logistic regression results.
Veterans who were not exposed to statin therapy at any time during the study
period were 1.56 times more likely to suffer all-cause mortality. In addition, veterans
who were exposed to N25% statin use during the study period were more likely to
remain alive, following a diagnosis of heart failure.
Effect of statin use post HF-ID: We identified a cohort of 5282 veterans with heart
failure diagnosis who were presumably started on statin therapy after the HF-ID to
assess for difference in survival time among four statin use stratifications. This subgroup
analysis was conducted to eliminate the bias of the unknown duration of statin therapy
prior to heart failure diagnosis. The demographic andmedication use of this cohort was
similar to the original cohort (see Appendix A). Kaplan–Meier analysis was done and the
omnibus Mantel–Cox log-rank test indicated significant differences in survival time
(χ32=259.27, pb0.001; Fig. 3). Analysis of pairwise comparisons employing the log-
rank test indicated survival time for veterans who did not initiate statin therapy was
significantly shorter in comparison to three other groups of statin users ( all pb0.001).
Logistic regression was performed on the cohort of 5282 veterans to identify the
association between incident statin use and all-cause mortality following diagnosis of
heart failure. No assumption violations were indicated. Similar to the results from the
previous cohort, the addition of the statin use stratifications to the model significantly
improved prediction of all-cause mortality (χ32=63.62, pb0.001). Further the variables
as a set with mortality (χ282 =661.25, pb0.001). The current model explains a larger
percentage of the variance in mortality than the original cohort (Nagelkerke R2=0.167
with 95% confidence limits from 0.144 to 0.182). The results of logistic regression are
presented in Table 3.
The results from this subgroup analysis indicated veterans who were not exposed
to statin therapy were 1.54 times more likely to suffer all-cause mortality. Veterans
who initiated statin therapy after the diagnosis of heart failure and maintained it for
N25% of the duration of the study period were more likely to remain alive, following a
diagnosis of heart failure. However, incremental benefit was not seen in N25% of statin
use similar to original cohort.
5. Discussion
The main findings of the study were that: [1] Statins decrease all-
cause mortality in this elderly heart failure population, [2] statin
therapy initiation and continuation for N25% of the duration after a
diagnosis of heart failure decreased all-cause mortality over a mean
follow-up period of 2.66 years.
The mean age of patients in our study was 72 years compared to
73 years in the
CORONA study and 68 years in GISSI-HF study. The mortality rate
in our study cohort was 25.8%, which is similar to the mortality rate in
GISSI-HF study (29%), but higher thanmortality rate in CORONA study
(11.6%) [22,23]. Our study, similar to GISSI-HF study evaluated the
effect of statins in both ischemic and nonischemic heart failure. The
reasons for differences in the mortality rates compared to CORONA
study are unclear, but could be due to differences in revascularization
Table 1
Descriptive characteristics stratified by percentage of time on statin following initiation of statin therapy (N=10,510).
Variable Statin use p value⁎
None N0 to 25% N25 to 75% N75%
(n=3044) (n=234) (n=1086) (n=6146)
Age at HF diagnosis (years) 73.57±11.38 71.39±10.44 68.86±10.70 71.79±9.50 b0.001
Follow-up time (days)† 919.37±504.18 982.58±497.54 967.03±506.87 1000.87±494.56 b0.001
Male 2981 (97.9%) 228 (97.4%) 1063 (97.9%) 6072 (98.8%) 0.003
All-cause mortality 1135 (37.3%) 54 (23.1%) 203 (18.7%) 1315 (21.4%) b0.001
Medications‡
ACE inhibitor 85.34±24.56 77.11±31.44 80.38±24.05 88.83±20.27 b0.001
ARB 86.40±23.85 78.05±34.12 84.91±19.20 85.91±23.97 b0.001
ASA 73.23±32.03 60.07±34.11 69.21±32.11 78.28±29.47 b0.001
Beta blocker 84.32±24.04 74.78±30.77 81.05±21.64 89.50±17.76 b0.001
Spironolactone 83.07±25.42 75.37±31.70 79.74±26.69 83.65±26.64 b0.001
Comorbid conditions
Atrial fibrillation 1125 (37.0%) 84 (35.9%) 337 (31.0%) 2141 (34.8%) 0.005
Cerebrovascular disease 329 (10.8%) 30 (12.8%) 113 (10.4%) 603 (9.8%) 0.258
Connective tissue disease 113 (3.7%) 8 (3.4%) 42 (3.9%) 285 (4.6%) 0.158
Coronary heart disease 1331 (43.7%) 154 (65.8%) 771 (71.0%) 4571 (74.4%) b0.001
Dementia 217 (7.1%) 12 (5.1%) 41 (3.8%) 247 (4.0%) b0.001
Depression 508 (16.7%) 38 (16.2%) 204 (18.8%) 1097 (17.8%) 0.340
Diabetes 901 (29.6%) 86 (36.8%) 489 (45.0%) 2743 (44.6%) b0.001
Hemorrhagic stroke 11 (0.4%) 0 (0.0%) 2 (0.2%) 14 (0.2%) 0.507
HIV 1 (0.0%) 0 (0.0%) 1 (0.1%) 2 (0.0%) 0.803
Hyperlipidemia 752 (24.7%) 153 (65.4%) 871 (80.2%) 5069 (82.5%) b0.001
Hypertension 2069 (68.0%) 179 (76.5%) 861 (79.3%) 4985 (81.1%) b0.001
Kidney disease 233 (7.7%) 24 (10.3%) 85 (7.8%) 458 (7.5%) 0.452
Liver disease 94 (3.1%) 5 (2.1%) 9 (0.8%) 57 (0.9%) b0.001
Lung disease 1265 (41.6%) 93 (39.7%) 434 (40.0%) 2339 (38.1%) 0.013
Malignancy 484 (15.9%) 35 (15.0%) 142 (13.1%) 813 (13.2%) 0.004
Peptic ulcer disease 91 (3.0%) 5 (2.1%) 37 (3.4%) 159 (2.6%) 0.350
Peripheral
arterial disease
307 (10.1%) 34 (14.5%) 178 (16.4%) 1004 (16.3%) b0.001
Sudden cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0.871
Data are presented as mean±SD or numbers (%).
ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blockers; ASA=acetylsalicylic acid; HF=heart failure; HIV=human immunodeficiency virus.
⁎ p values for omnibus tests across the 4 groups.
† Number of days in study following heart failure diagnosis.
‡ Number of veterans on each medication differed by statin use stratification.
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rates, aggressive lipid control and other co-morbidities. The effect of
cardioprotective medications could have been more substantial in
patients with ischemic heart failure as opposed to patients with
nonischemic heart failure. This could also explain the reason for the
lack of additional benefit seen with statins in the CORONA study. Our
study had mortality rates similar to that seen in the heart failure
population of the Framingham study, underscoring the fact that the
VA represents a large diverse population [29].
Several trials have been published to date that have evaluated the
effect of statins on incidence of heart failure and mortality [13–20].
Most of the data evaluating the effect of statins on heart failure has
been obtained from retrospective analyses of clinical trials. Treatment
with statins consistently resulted in significant decrease in mortality
across multiple clinical trials. The main limitation of these large
databases is that statin therapy was recorded at single time in the
study, mostly at discharge diagnosis. Considering the high prevalence
of ischemic heart disease, the beneficial effect of statins in these trials
was attributed to reduction in the incidence of ischemic complica-
tions. However, few prospective trials have also studied the effect of
statins on patients with non ischemic cardiomyopathy and showed
improvement in symptoms [13,16,17] and improvement in mortality
[18,19]. Previous retrospective studies have largely focused on
selected subgroups of patients with heart failure. Moreover there
were lack of serial cross sectional data on statin exposure, smaller
sample sizes and incomplete adjustments for the effects of concurrent
treatments and their compliance. Our patient population was large
with multiple comorbidites among 5 different states in the Midwest
with equal access to care. All the patients at the Veterans Healthcare
System receive lipid lowering therapy based on national guidelines.
Medication compliance is an important factor in consideration of the
treatment of patients with heart failure. We evaluated all the patients
based on the duration of use of statins during the study period. To our
knowledge, this is the first study that looked at the differences in the
duration of statin use and all-cause mortality and elucidated that the
patient had to be receiving enough to provide power for stratified
analysis. We also tried to control for the comorbidites, which could
significantly affect the all-cause mortality. All the veterans get their
medicines from the Veterans Health Care System either free or at
minimal cost, thus all the statin and other cardioprotective drugs
were accounted for in our study, including adjusting for concurrent
medication usage and the duration of their usage.
CORONA study randomized 5011 patients with NYHA class II to IV
heart failure patients [22]. In this trial, treatment with rosuvastatin
was not associated with significant improvement in the primary
endpoint, whichwas a composite of death from cardiovascular causes,
non fatal myocardial infarction or nonfatal stroke. In this trial, the rate
of atherothrombotic events was relatively low in a short duration
(2.7 years) and majority of deaths were due to worsening HF, which
reflects patients with advanced HF. The study included older patients
withmoderate to severe heart failurewhowere NYHA functional class
III or IV in which the disease was probably too advanced to modify
(60% of patients were NYHA III). Thus the primary endpoint may not
have captured the beneficial effects of rosuvastatin in this elderly
group with advanced HF. There was significant decrease in HF
hospitalization (secondary endpoint), which is more related to
decreased ischemic episodes. Our study included patients who were
captured at the first known diagnosis of heart failure and thus the
patients were effectively initiated on a statin when the disease was
modifiable. Recent meta-analysis that evaluated 13 studies including
CORONA study showed that there was 26% decrease in relative risk of
mortality among statin users, similar to our finding [20].
Fig. 2. Unadjusted survival function stratified by percentage of time on statin following
initiation of statin therapy (N=10,510).
Table 2
Results of adjusted logistic model for primary analysis (N=10,510).
Statin use n B SE OR 95% CI p
Lower Upper
None 3044 0.445 0.060 1.561 1.389 1.755 0.000
N0 to 25% 234 −0.122 1.230 0.885 0.695 1.128 0.324
N25 to 75% 1086 −0.213 0.075 0.808 0.698 0.936 0.004
N75% 6146 −0.111 0.054 0.895 0.805 0.995 0.040
N — total number of patients in all the groups, n — number of patients in each statin
group, B — coefficient, SE — standard error, OR — odds ratio, CI — confidence interval,
p — p value.
Fig. 3. Unadjusted survival function stratified by percentage of time on statin for
veterans only initiating statin therapy following heart failure diagnosis (N=5282).
Table 3
Results of adjusted logistic model for sub-analysis (N=5282).
Statin use n B SE OR 95% CI p
Lower Upper
None 3044 0.434 0.077 1.543 1.328 1.793 0.000
N0 to 25% 135 0.006 0.164 1.006 0.730 1.388 0.969
N25 to 75% 355 −0.249 0.121 0.779 0.614 0.989 0.040
N75% 1748 −0.191 0.082 0.826 0.704 0.970 0.020
N — total number of patients in all the groups, n — number of patients in each statin
group, B — coefficient, SE — standard error, OR — odds ratio, CI — confidence interval,
p — p value.
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Table S1
Descriptive characteristics of veterans initiating statin use post HF-ID (N=5282).
Variable Statin Use p Value*
None (n=3044) N0 to 25% (n=135) N25 to 75% (n=355) N75% (n=1748)
Age at HF diagnosis 73.57±11.38 69.99±10.81 68.59±11.13 70.39±10.03 b0.001
Follow-up time (days)† 919.37±504.18 1107.28±489.18 1135.08±519.59 1116.79±488.11 b0.001
Male 2981 (97.9%) 132 (97.8%) 348 (98.0%) 1725 (98.7%) 0.293
All-cause mortality 1135 (37.3%) 32 (23.7%) 64 (18.0%) 340 (19.5%) b0.001
Medications‡
ACE 85.34±24.56 74.29±32.68 78.45±24.70 89.26±19.40 b0.001
ARB 86.40±23.85 81.14±32.00 86.50±15.94 84.96±25.88 0.152
ASA 73.23±32.03 42.71±34.59 69.31±31.77 75.14±31.12 b0.001
Beta Blocker 84.32±24.04 72.79±33.44 78.68±24.00 89.70±16.81 b0.001
Spironolactone 83.07±25.42 72.19±34.74 78.29±25.37 84.81±25.30 0.010
Comorbid Conditions
Atrial Fibrillation 1125 (37.0%) 50 (37.0%) 109 (30.7%) 602 (34.4%) 0.064
Cerebrovascular Disease 329 (10.8%) 21 (15.6%) 31 (8.7%) 183 (10.5%) 0.178
Connective Tissue Disease 113 (3.7%) 4 (3.0%) 11 (3.1%) 65 (3.7%) 0.909
Coronary Heart Disease 1331 (43.7%) 78 (57.8%) 217 (61.1%) 1188 (68.0) b0.001
Dementia 217 (7.1%) 5 (3.7%) 9 (2.5%) 55 (3.1%) b0.001
Depression 508 (16.7%) 22 (16.3%) 66 (18.6%) 285 (16.3%) 0.771
Diabetes 901 (29.6%) 51 (37.8%) 136 (38.3%) 693 (39.6%) b0.001
Hemorrhagic Stroke 11 (0.4%) 0 (0.0%) 0 (0.0%) 5 (0.3%) 0.604
HIV 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.865
Hyperlipidemia 752 (24.7%) 85 (63.0%) 238 (67.0%) 1257 (71.9%) b0.001
Hypertension 2069 (68.0%) 102 (75.6%) 250 (70.4%) 1327 (75.9%) b0.001
Kidney Disease 233 (7.7%) 18 (13.3%) 23 (6.5%) 135 (7.7%) 0.081
Liver Disease 94 (3.1%) 4 (3.0%) 3 (0.8%) 20 (1.1%) b0.001
Lung Disease 1265 (41.6%) 48 (35.6%) 131 (36.9%) 613 (35.1%) b0.001
Malignancy 484 (15.9%) 16 (11.9%) 48 (13.5%) 198 (11.3%) b0.001
Peptic Ulcer Disease 91 (3.0%) 4 (3.0%) 14 (3.9%) 44 (2.5%) 0.499
Peripheral Arterial Disease 307 (10.1%) 15 (11.1%) 44 (12.4%) 242 (13.8%) 0.001
Sudden Cardiac Death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Data are presented as mean±SD or numbers (%).
* p Values for omnibus tests across the 4 groups.
ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blockers; ASA=acetylsalicylic acid; HF=heart failure; HIV=human immunodeficiency virus.
† Number of days in study following heart failure diagnosis.
‡ Number of veterans on each medication differed by statin use stratification.
Compliance with statin therapy is a major confounder in the
observational studies and GISSI-HF trial [23]. GISSI-HF study random-
ized 4574 patients (40% ischemic, 60% NYHA II) to treatment with
rosuvastatin and placebo. There was no difference in any endpoints
and this led them to conclude that statins can be discontinued in HF, if
there are no other indications. One of the main limitations in the
GISSI-HF study was that 1/3 rd of study patients were not compliant
with treatment due to various reasons. As shown in our study, patients
who used statin for b25% had no benefit and the improvement in
mortality was apparent only when the statin was N25% of the
duration. In the Kaplan–Meier analysis, the patients who used the
statin for b25% of the time had survival curves approach those with no
statin use, during the latter half of the follow-up period (Figs. 2 and 3).
This was similar to the myocardial infarction trials, where discontin-
uation of statins increased all-cause mortality [30]. Based on our
study, the benefit was seen within a relatively short duration (within
1 year) after starting statins and in patients with b25% use of statins,
there was no mortality benefit.
CORONA and GISSI-HF trials evaluated the effect of one type of
statin use on heart failure and there is no conclusive evidence of class
effect of statins. Our study evaluated effects of various types of statins
in patients with both ischemic and non ischemic heart failure.
Majority of the patients in this study population were on simvastatin
(85%) and atorvastatin (4.5%). These statins have been specifically
associated with improved mortality rates in heart failure patients
[6,14–16,24]. There has been only one study evaluating the class effect
of statins in a large population based study with congestive heart
failure, but this did not evaluate rosuvastatin [24].
The lack of incremental benefit between patients with 26–75% of
statin use as opposed to N75%of statin usewas a surprisingfinding tous.
This could be due to nature of the study or it could mean that effect of
statin may reach a plateau after certain period in heart failure patients.
Our study has a few limitations. As a retrospective study, we
cannot completely rule out the effect of confounding factors.We could
not control for certain prognostic factors such as heart rate, blood
pressure, left ventricular ejection fraction and cholesterol levels. In
older heart failure patients the ejection fraction plays a lesser role than
etiology in predicting overall mortality, as shown in the Framingham
study [29]. The study includes veterans, so the predominant
population is male sex. Race data were missing in 48% of patients in
non random fashion.
In conclusion, our study showed statin use was significantly
associated with decrease in all-cause mortality following the diagnosis
of heart failure. Patients who were not exposed to statin therapy were
1.56 timesmore likely to suffer all-causemortality during the followupof
2.66 years. This is the first study to our knowledge evaluating the graded
relation between statin use and mortality in heart failure patients.
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